$AUROPHARMA a Share In Focus: Nuvama hikes target for pharma stock after $250 mn Lannett buyout nod

Aurobindo Pharma Share Price Target 2026: Brokerage firm Nuvama has delivered a bullish outlook on Aurobindo Pharma’s stock after the company said its arm Aurobindo Pharma USA, Inc had received approval from the US Federal Trade Commission (FTC) for its USD 250 million acquisition of Lannett Company LLC. At 9:29 AM today, shares of Aurobindo Pharma were trading at Rs 1524.00, up 2.12 per cent from the previous close on the BSE.